Dose Form Development
Catalent is the leading global provider of advanced drug delivery technologies and development solutions, providing worldwide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. The company has over 80 years’ experience serving the industry, and proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable product supply.
Catalent’s solutions include analytical, pre-formulation and formulation, the recent addition of spray dry dispersion specialist Pharmatek, and biologics technologies and manufacture. Catalent now offers the most comprehensive toolkit of bioavailability enhancing technologies and the development of patient centric dose forms.
Catalent serves thousands of innovators, both established and emerging, in over 80 markets, including 48 of the top 50 pharmaceutical and 41 of the top 50 biotech companies. Its team of over 1,400 talented scientists has supported over half of all new molecular entities approved by the FDA in the past 10 years, and from more than 30 global sites it supplies more than 70 billion units annually, to customers in over 80 countries.
Whether an innovator is looking for a single, tailored solution, or multiple answers throughout a product’s lifecycle, Catalent can improve the total value of treatments, from discovery to market and beyond.
Catalent. More products. Better treatments. Reliably supplied.™
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
